Biosimilars – Forecast – Forecast Methodology and General Market Assumptions
In 2024, sales of branded biologics for oncology (except G-CSFs), immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $160 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Sales of biosimilars in these therapy areas and countries totaled approximately $19 billion. Throughout our 2024-2034 forecast period, increasing numbers of branded biologics are set to lose patent protection, and we expect biosimilars to enter the market and erode patient share and drug prices, generating savings of approximately $37 billion to healthcare systems. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Forecast - Forecast Methodology and General Market Assumptions
